After a quick start out the gates in 2012, the European Commission proceeded to carry out a lengthy review of its bioeconomy strategy – slamming the brakes on investor interest in EU biotechs developing solutions for the move to a low-carbon, zero-waste economy. Following several reports that suggested the bloc will miss internationally agreed sustainability targets, the EC now wants to speed up the switch to biobased production. Industry stakeholders presented a huge range of promising technologies at the EFIB, but are still awaiting the go-ahead.
Sanofi appoints Ameet Nathwani
AppointmentsSanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer.
Afyren raises €21m to launch production plant
Latest NewsFrench industrial biotech company Afyren announced a capital increase of €21m in a financing round led by Sofinnova Partners and Valquest Partners to scale up its biobased organic acid production to industrial scale.
Race against time
BackgroundAfter a quick start out the gates in 2012, the European Commission proceeded to carry out a lengthy review of its bioeconomy strategy – slamming the brakes on investor interest in EU biotechs developing solutions for the move to a low-carbon, zero-waste economy. Following several reports that suggested the bloc will miss internationally agreed sustainability targets, the EC now wants to speed up the switch to biobased production. Industry stakeholders presented a huge range of promising technologies at the EFIB, but are still awaiting the go-ahead.
Industrial biotech hub validates start-up ideas
Latest Newsuniqure delivers POC for hemophilia B gene therapy
Latest NewsGene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Pharma gets clinical milestone for IL7R antagonist
Latest NewsOse Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016.
How stroma cells trigger tumour angiogenesis
Latest NewsAnalyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Kiadis Pharma appoints Dr. Robert Friesen as CSO
AppointmentsKiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019.
Jennewein Biotechnologie expands into Chinese market
Latest NewsMedicxi put €40m into two Sosei spin off companies
Latest NewsSosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.